Normative data for COGITAB: An Italian tablet-based test battery conceived for the preclinical phase of Alzheimer's disease.
Saved in:
| Title: | Normative data for COGITAB: An Italian tablet-based test battery conceived for the preclinical phase of Alzheimer's disease. |
|---|---|
| Authors: | Beltrami, Daniela (AUTHOR), Barletta-Rodolfi, Caterina (AUTHOR), Bertini, Flavio (AUTHOR), Braglia, Luca (AUTHOR), Calzà, Laura (AUTHOR), Corbo, Massimo (AUTHOR), Gasparini, Federico (AUTHOR), Marti, Alessandro (AUTHOR), Montesi, Danilo (AUTHOR), Pisano, Marta (AUTHOR), Rusconi, Maria Luisa (AUTHOR), Sozzi, Matteo (AUTHOR), Tonon, Cecilia (AUTHOR), Ghidoni, Enrico (AUTHOR) |
| Source: | Applied Neuropsychology: Adult. May/Jun2025, Vol. 32 Issue 3, p664-674. 11p. |
| Subjects: | Disease risk factors, Alzheimer's disease, Mild cognitive impairment, Medical screening, Neuropsychological tests |
| Abstract: | The number of people with dementia is increasing worldwide. Two main approaches have been adopted to identify subjects with Alzheimer's disease (AD): the neuropsychological evaluation and the identification of biomarkers of AD. The first method is less invasive and easier to perform. This study assesses the psychometric properties of COGITAB, a novel web application d esigned to be sensitive to the subtle cognitive changes distinctive of the early Mild Cognitive Impairment (MCI) and the preclinical phase of AD. We enrolled 518 healthy controls, classified according to several risk factors and the presence of a family history of dementia. The participants were given COGITAB after a neuropsychological screening. The COGITAB Total Score (TS) was significantly affected by age and years of education. Acquired risk factors and family history of dementia significantly impacted only the COGITAB total execution time (TET), not the TS. This study provides normative data for a newly developed web application. Control subjects with acquired risk factors performed slower, giving an important role to the TET recording. Further studies should examine the ability of this new technology to discriminate between healthy subjects and subjects with initial cognitive decline, even when not detected by standard neuropsychological assessments. [ABSTRACT FROM AUTHOR] |
| Copyright of Applied Neuropsychology: Adult is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The number of people with dementia is increasing worldwide. Two main approaches have been adopted to identify subjects with Alzheimer's disease (AD): the neuropsychological evaluation and the identification of biomarkers of AD. The first method is less invasive and easier to perform. This study assesses the psychometric properties of COGITAB, a novel web application d esigned to be sensitive to the subtle cognitive changes distinctive of the early Mild Cognitive Impairment (MCI) and the preclinical phase of AD. We enrolled 518 healthy controls, classified according to several risk factors and the presence of a family history of dementia. The participants were given COGITAB after a neuropsychological screening. The COGITAB Total Score (TS) was significantly affected by age and years of education. Acquired risk factors and family history of dementia significantly impacted only the COGITAB total execution time (TET), not the TS. This study provides normative data for a newly developed web application. Control subjects with acquired risk factors performed slower, giving an important role to the TET recording. Further studies should examine the ability of this new technology to discriminate between healthy subjects and subjects with initial cognitive decline, even when not detected by standard neuropsychological assessments. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 23279095 |
| DOI: | 10.1080/23279095.2023.2219797 |
